Recent Acquisition BioAgilytix's acquisition of MicroConstants in 2021 indicates a strategic expansion into bioanalytical services for large molecules, presenting opportunities to offer innovative technologies and collaborative solutions tailored to their growing portfolio.

Expertise in Bioanalysis MicroConstants specializes in regulated bioanalysis and pharmacokinetic analysis supporting drug development, highlighting a potential demand for advanced analytical instruments, methods, and outsourcing collaborations within their projects.

Growing Industry Presence With a history dating back to 1998 and a dedicated focus on small and large molecule analysis, the company’s established reputation can be leveraged to introduce new research techniques, instrumentation, and testing platforms to improve efficiency and compliance.

Market Focus Targeting biotech and pharmaceutical clients globally, there is an opportunity to provide specialized reagents, assay kits, and laboratory automation tools that align with their scientific needs and support their drug discovery pipelines.

Service Expansion MicroConstants has expanded its services to nanoparticle formulation development and biomarker research, indicating a potential market for complementary technologies such as multiplex assay systems, high-throughput screening, and data analytics to enhance their service offerings.